What were the key breakthroughs at the ASH Annual Meeting 2025 for multiple myeloma?

The ASH 2025 meeting presented unprecedented data showing significant advances in multiple myeloma treatment, including potential functional cures.

Which companies presented promising data at ASH 2025 for multiple myeloma?

Major pharmaceutical developers like Johnson & Johnson, Arcellx, and Gilead presented pivotal data at ASH 2025 for multiple myeloma.

Is a functional cure for multiple myeloma possible after the ASH 2025 meeting?

Yes, recent data from the ASH 2025 meeting suggests that long-term disease-free survival and potential functional cures are becoming a reality for multiple myeloma patients.

Home / Health / Multiple Myeloma Cure Closer: ASH Meeting Shocks

Multiple Myeloma Cure Closer: ASH Meeting Shocks

12 Dec

•

Summary

ASH 2025 showcased unprecedented data for multiple myeloma treatments.
Johnson & Johnson's TECVAYLI plus DARZALEX showed significant PFS benefit.
New therapies suggest long-term survival and potential functional cures.

Multiple Myeloma Cure Closer: ASH Meeting Shocks

Groundbreaking clinical advances in multiple myeloma treatment were unveiled at the 67th American Society of Hematology (ASH) Annual Meeting held December 6-9, 2025. Leading biopharmaceutical companies presented unprecedented efficacy data, suggesting that long-term disease-free survival, and potentially a 'functional cure,' is within reach for more patients. Novel immunotherapies and targeted agents are reshaping the treatment landscape.

Johnson & Johnson's late-breaking results from the Phase III MajesTEC-3 study highlighted the combination of TECVAYLI and DARZALEX FASPRO. This combination showed the most impressive progression-free survival (PFS) benefit ever seen in a Phase III multiple myeloma trial, with a hazard ratio of 0.17. After three years, 83.4% of patients on this regimen remained alive and progression-free.